Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma

Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma

<p><strong>Purpose</strong><br/> Our purpose was to describe the patterns and predictors of treatment failure in patients receiving definitive chemoradiation therapy (CRT) for anal squamous cell carcinoma (ASCC), delivered using intensity modulated radiation therapy (IMRT).&l...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Shakir, R, Adams, R, Cooper, R, Downing, A, Geh, I, Gilbert, D, Jacobs, C, Jones, C, Lorimer, C, Namelo, W, Sebag-Montefiore, D, Shaw, P, Muirhead, R
Natura:	Journal article
Lingua:	English
Pubblicazione:	Elsevier 2019

Documenti analoghi

Toxicity, tolerability & compliance of concurrent capecitabine or 5-fluorouracil in the radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort
di: Jones, C, et al.
Pubblicazione: (2018)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
di: Robinson, M, et al.
Pubblicazione: (2019)

Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: From consensus guidance to large-scale prospective audit, prior to future clinical trials
di: Gilbert, D, et al.
Pubblicazione: (2016)

Personalized dose escalation in anal cancer
di: Robinson, M, et al.
Pubblicazione: (2016)

Changes in pelvic active bone marrow seen on FDG-PET in patients receiving concurrent chemoradiation for anal cancer
di: Robinson, M, et al.
Pubblicazione: (2018)

A novel pretrial contouring exercise for the UK led PersonaLising Anal cancer radioTherapy dOse (PLATO) trial
di: Robinson, M, et al.
Pubblicazione: (2017)

Initial results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015
di: Muirhead, R, et al.
Pubblicazione: (2016)

Is there a role for a biological boost in squamous cell anal cancer?
di: Sabbagh, A, et al.
Pubblicazione: (2018)

Oncologic outcomes of squamous cell carcinoma of the anal canal after chemoradiation therapy
di: Dae Ro Lim, et al.
Pubblicazione: (2016-06-01)

Treatment planning of dose escalation for anal cancer in the PLATO trial
di: Abbott, N, et al.
Pubblicazione: (2017)

Is there a role for an FDG derived biological boost in squamous cell anal cancer?
di: Sabbagh, A, et al.
Pubblicazione: (2018)

Early stage anal margin cancer: towards evidence‐based management
di: Renehan, A, et al.
Pubblicazione: (2019)

Is there a role for an 18F-fluorodeoxyglucose-derived biological boost in squamous cell anal cancer?
di: Sabbagh, A, et al.
Pubblicazione: (2018)

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
di: Dewas Claire, et al.
Pubblicazione: (2012-11-01)

Prognostic factors for patients with anal cancer treated with conformal radiotherapy—a systematic review
di: Stelios Theophanous, et al.
Pubblicazione: (2022-06-01)

Proton beam therapy – the challenges of delivering high-quality evidence of clinical benefit
di: National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group, et al.
Pubblicazione: (2018)

Combining sonodynamic therapy with chemoradiation for the treatment of pancreatic cancer
di: Browning, RJ, et al.
Pubblicazione: (2021)

Tracheal-Mediastinal Fistula Post-chemoradiation Therapy
di: Joseph McCarthy, et al.
Pubblicazione: (2014-11-01)

Chemoradiation therapy for localized colorectal cancer: a view from the outside
di: F. Sh. Akhmetzyanov, et al.
Pubblicazione: (2023-01-01)

Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: A mono-institutional retrospective analysis
di: Alessandra Arcelli, et al.
Pubblicazione: (2019-02-01)

Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer.
di: Warren, S, et al.
Pubblicazione: (2014)

Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.
di: MacGregor, T, et al.
Pubblicazione: (2012)

Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer
di: Warren, S, et al.
Pubblicazione: (2017)

Optimising RT dose for anal cancer - the development of three clinical trials in one platform
di: Sebag-Montefiore, D, et al.
Pubblicazione: (2017)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
di: Kelsey L. Corrigan, MD, MPH, et al.
Pubblicazione: (2022-07-01)

Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study
di: William Chu, et al.
Pubblicazione: (2023-06-01)

Neoadjuvant chemoradiation therapy for soft tissue sarcomas of the extremities
di: Samuel Aguiar Junior, et al.
Pubblicazione: (2009-11-01)

Results of implementation of a program of individual support of chemoradiation therapy in patients with head and neck tumors
di: A. R. Gevorkov, et al.
Pubblicazione: (2021-01-01)

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
di: Mukherjee, S, et al.
Pubblicazione: (2018)

Comparison of radiation therapy alone and concurrent chemoradiation therapy for in operable cervical cancer
di: Md. Zillur Rahman Bhuiyan, et al.
Pubblicazione: (2016-08-01)

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer
di: Marissa B. Savoie, et al.
Pubblicazione: (2019-09-01)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
di: Mukherjee, S, et al.
Pubblicazione: (2017)

MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection.
di: Honsoul Kim, et al.
Pubblicazione: (2016-01-01)

Non surgical therapy for chronic anal fissure
di: M. V. Abritsova, et al.
Pubblicazione: (2022-05-01)

Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
di: Brunner, T, et al.
Pubblicazione: (2008)

DNA-Platinum Thin Films for Use in Chemoradiation Therapy Studies
di: Mohammad Rezaee, et al.
Pubblicazione: (2012-01-01)

Achalasia Combined with Esophageal Cancer Treated by Concurrent Chemoradiation Therapy
Pubblicazione: (2009-12-01)

Effect of GSDMB polymorphism on sensitivity to chemoradiation therapy for cervical cancer
di: Ni Zhong, et al.
Pubblicazione: (2021-12-01)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
di: Casadei-Gardini A, et al.
Pubblicazione: (2019-04-01)

Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma
di: Fang He, et al.
Pubblicazione: (2024-12-01)